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The helminth product, ES-62 
modulates dendritic cell responses 
by inducing the selective 
autophagolysosomal degradation 
of TLR-transducers, as exemplified 
by PKCδ
Russell J. Eason1, Kara S. Bell2, Fraser A. Marshall1, David T. Rodgers1, Miguel A. Pineda1, 
Christina N. Steiger1, Lamyaa Al-Riyami2, William Harnett2 & Margaret M. Harnett1
We have previously shown that ES-62, a phosphorylcholine (PC)-containing glycoprotein secreted 
by the parasitic filarial nematode Acanthocheilonema viteae targets dendritic cell (DC) responses, 
specifically by suppressing TLR4 signalling to inhibit Th1/Th17-driven inflammation. We have now 
investigated the molecular mechanisms underpinning such immunomodulation and show here that 
ES-62-mediated downregulation of protein kinase C-δ (PKC-δ), a TLR4-associated signalling mediator 
required for full activation of LPS-driven pro-inflammatory responses, is associated with induction of 
a low level of autophagic flux, as evidenced by upregulation and trafficking of p62 and LC3 and their 
consequent autophagolysosomal degradation. By contrast, the classical TLR4 ligand LPS, strongly 
upregulates p62 and LC3 expression but under such canonical TLR4 signalling this upregulation appears 
to reflect a block in autophagic flux, with these elements predominantly degraded in a proteasomal 
manner. These data are consistent with autophagic flux acting to homeostatically suppress 
proinflammatory DC responses and indeed, blocking of PKC-δ degradation by the autophagolysosomal 
inhibitors, E64d plus pepstatin A, results in abrogation of the ES-62-mediated suppression of LPS-
driven release of IL-6, IL-12p70 and TNF-α by DCs. Thus, by harnessing this homeostatic regulatory 
mechanism, ES-62 can protect against aberrant inflammation, either to promote parasite survival or 
serendipitously, exhibit therapeutic potential in inflammatory disease.
We have previously shown that ES-62, a phosphorylcholine (PC)-containing immunomodulatory glycopro-
tein secreted by the filarial nematode Acanthocheilonema viteae, is protective in mouse models of allergic1–3 
and autoimmune4–6 disease. Such protection is associated with homeostatic resetting of the IL-23/IL-17/IL-22 
inflammatory axis, which appears to become dysregulated in these inflammatory disorders: a key effector driving 
development of this type of inflammation is the dendritic cell (DC), which ES-62 targets by subverting TLR4 
signalling7–9 to suppress aberrant DC-priming of Th17 cells and IL-17-producing γ δ T cells2,4.
Although ES-62 requires TLR4 for its actions on DCs7,8, unlike the canonical TLR4 ligand LPS10, it does 
not signal for robust proinflammatory responses or downregulate TLR4 expression in these cells7,8,11. Rather, 
and more like the non-toxic species of LPS from Rhodobacter sphaeroides12,13 or Bacteroides dorei14, expo-
sure to ES-62 dampens DC responses to challenge with LPS7,8,11. LPS internalises and trafficks TLR4 via a 
clathrin-dependent endosomal mechanism, initially to couple to the pro-inflammatory TRAM/TRIF signalling 
pathway and then ultimately, by promoting antigen (Ag)-presentation, to link innate and adaptive responses 
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(reviewed in refs 10 and 11). Intriguingly, therefore, R. sphaeroides LPS and ES-62 are internalised and traf-
fick TLR4 in a clathrin-independent manner (reviewed in ref. 11): indeed, and of relevance given the increas-
ing evidence that caveolae/lipid rafts act as sensors to regulate signalling15, ES-62, which is internalised in a 
TLR4-dependent-manner in mast cells and macrophages1,16 induces the caveolae/lipid raft-dependent sequestra-
tion and autophagolysosomal degradation of TLR4-associated protein kinase C (PKC)-α in mast cells1,17.
The precise mechanism(s) underpinning differential LPS- and ES-62-mediated TLR4 signalling in 
DCs has yet to be fully resolved: however, our recent data indicating that ES-62, but not LPS, can drive the 
autophagolysosomal-mediated downregulation of MyD88 in DCs under hyper-inflammatory conditions9 sug-
gests that ES-62 may generally act by harnessing homeostatic autophagy-dependent mechanisms to limit aberrant 
inflammation by degrading key TLR4 signal effectors. In support of this, whilst autophagy is a critical and com-
plex cellular homeostatic mechanism with key roles in TLR-associated immunity, notably in killing of intracel-
lular pathogens, antigen presentation and T cell polarisation, it also controls inflammation, acting to antagonise 
inflammasome signalling and to limit and resolve inflammation18. Therefore, we have now investigated whether 
ES-62 induces autophagolysosomal degradation of key effectors and known targets of the helminth product, such 
as the protein kinase C (PKC) isoforms (α , δ and ε ) associated with the LPS/TLR4 cassette19,20, in an attempt to 
explain, how ES-62 subverts pro-inflammatory TLR4 signalling in DCs to reset Th cell polarisation.
We show that both LPS and ES-62 can upregulate components (p62 and LC3) of the autophagy machinery: 
however, whilst LPS-mediated pro-inflammatory responses are associated with (proteasomally-regulated) cyto-
solic p62 and PKC-δ signalling, and autophagic flux blockade, ES-62 acts to limit such cytosolic signalling by 
selectively inducing autophagolysosomal degradation of these elements. Moreover, blocking of autophagolyso-
somal degradation relieves ES-62-mediated suppression of LPS production of IL-6, IL-12p70 and TNFα by DCs, 
key mediators that contribute to pathogenic Th cell polarisation and inflammation in allergy and autoimmunity.
Results
ES-62 modulates DC function in vitro and in vivo. ES-62 exhibits the ability to modulate Th1-, Th17- 
and Th22-mediated responses, particularly when these phenotypes are dysregulated during development of 
pathogenesis in mouse models of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and asthma2,4–6. 
For example, in the Collagen-Induced Arthritis (CIA) model of RA where Th1/Th17 responses are pathogenic, 
ES-62 targets DCs to suppress their priming of such aberrant Th and γ δ T cells4. Consistent with this, ES-62 not 
only inhibits LPS-stimulated production of TNFα by DCs but also that of IL-6, IL-12p70 and IL-23, cytokines 
that promote development of IFNγ - and IL-17-producing T cells (Fig. 1a). Reflecting this, such ES-62-treated 
DCs exhibited reduced capacity to polarise Th17 or Th22 responses, both at the protein and mRNA level (Fig. 1b). 
Figure 1. ES-62 inhibits LPS-stimulated DC responses. (a) Levels of TNFα , IL-6, IL-12p70, and IL-23 
released by bmDCs derived from BALB/c mice incubated in medium alone (None) or containing ES-62 
(2 μ g/ml) for 18 h prior to culture in medium alone or containing LPS (1 μ g/ml) for a further 18 h. Data are 
collated from 3 experiments and represent the means (of means of triplicate estimates from the independent 
experiments) ± SEM; **p < 0.01 and ***p < 0.001, relative to the LPS group. (b) BmDCs treated as described 
in a, were pulsed with OVA323–339 and co-cultured with OVA-specific KJ1.26+CD4+CD62L+ T cells for 72 h 
before measurement of IL-17A and IL-22 release by ELISA or determination of mRNA levels in the cells by 
qRT-PCR. Relative quantitation (Rq) of mRNA levels was defined by 2^−Δ Δ Ct values obtained relative to 
the house-keeping reference gene (GAPDH) and experimental control samples, namely the medium-only DCs 
(None; 0 nM OVA peptide). Data are the mean values ± SD, n = 3, from a single experiment where **p < 0.01 
and ***p < 0.001 for ES-62+ LPS-treated cells relative to the cells incubated with LPS alone. The ability of LPS-, 
but not ES-62-matured bmDCs from BALB/c mice to prime IL-17 release by KJ1.26+CD4+CD62L+ T cells was 
found in 3 additional independent experiments whilst LPS-, but not ES-62-matured bmDCs from C57BL/6 
mice were shown to prime IL-17 and IL-22 release by OTII CD4+CD62L+ T cells in a further independent 
experiment (data not shown).
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Moreover, and mirroring the in vivo modulation of Ag-specific clonal expansion and Th1/Th17 cell polarisation 
by ES-6221, these effects are replicated in vivo as recipient mice receiving transfer of DCs exposed to ES-62+ LPS 
show both reduced clonal expansion of OVA-specific Th cells (Fig. 2a,b) and production of proinflammatory 
cytokines associated with such effector responses upon restimulation of draining lymph node (DLN) cells ex vivo 
(Fig. 2b), relative to those receiving control LPS-matured DC (pre-treated with medium alone). Thus, although 
ES-62 and LPS both signal via TLR4 on DCs7,8, exposure of DCs to ES-62 alone does not stimulate the classical 
effector mechanisms (pro-inflammatory cytokine production and priming of Th1/Th17 proliferation and differ-
entiation) of canonical TLR ligands, either in vitro or in vivo: these data therefore confirm and extend our evi-
dence obtained to date (reviewed in refs 9 and 11) that ES-62 and LPS exploit differential TLR4 effector pathways.
ES-62 selectively targets PKC-δ for downregulation in DCs. We have previously shown that the α , 
δ and ε isoforms of PKC regulate TLR4 signalling in mast cells and that ES-62 subverts such TLR4 signalling by 
downregulating expression of MyD88 and PKC-α and PKC-δ 1,17,22: consistent with a similar mode of action in 
DCs, ES-62 acts homeostatically to limit expression of MyD88 which is upregulated in DCs under inflammatory 
conditions9. We therefore next investigated whether the α , δ and ε isoforms of PKC played key roles in LPS/
TLR4-mediated cytokine responses in bmDCs and whether their differential signalling by ES-62 and LPS could 
provide a rationale for the observed distinct functional outcomes.
Firstly, analysis of PKC-α expression showed that exposure of DCs to either ES-62 or LPS resulted in some 
upregulation of this signalling element (Fig. 3ai,ii). The lack of any differential effect presumably reflects that 
PKC-α does not appear to be essential for LPS-stimulated cytokine secretion as indicated by experiments in 
bmDCs from PKC-α -deficient mice (Fig. 3aiii): rather, LPS-stimulated TNFα production appeared to be 
increased in such bmDCs. Similarly, although LPS, but not ES-62, induced an increase in PKC-ε expression 
(Fig. 3bi,ii), this isoform was also found to be dispensable for LPS-mediated cytokine responses (Fig. 3biii). 
Moreover, the ES-62-mediated inhibition of LPS-stimulated IL-6 responses was found to be intact in bmDCs 
from either PKC-α or -ε KO mice (Fig. 3c).
Interestingly therefore, given that PKC-δ plays key roles in DC development and motility, IL-12p40/p70 
production, MHC II-Ag presentation and polarisation of Th1 responses23–26, whereas ES-62 reproducibly 
decreased (0.56 ± 0.04 of control value at 18 h, n = 12 independent experiments p < 0.001) expression of this 
isoform (Fig. 3di,ii), LPS had little effect (1.05 ± 0.13 of control value at 18 h, n = 10 independent experiments). 
As PKC-δ plays a key role in development of DCs from haemopoietic stem cells26, rather than derive bmDCs from 
PKC-δ -deficient mice, we tested the effect of PKC-δ -specific siRNA on LPS-mediated DC responses: this showed 
that, as with ES-62, partial knockdown of PKC-δ expression by siPKC-δ resulted in significant (~25%) inhibition 
of LPS-mediated IL-12p70 release but perhaps surprisingly, had no effect on the production of another IL-12 
family cytokine, IL-23 (Fig. 3diii).
ES-62 induces autophagolysosomal degradation of PKC-δ in DCs. Currently, the role(s) of auto-
phagy in TLR-mediated innate and adaptive immunity remains to be fully delineated, as the complexity of the 
system has resulted in data supporting both inflammation-promoting and -resolving roles for this apparently 
critical cellular homeostatic mechanism18. In any case, stimulation of DCs with either ES-62 or LPS induces cel-
lular trafficking of the key autophagy element, p62 (Fig. 4a) to vesicular compartments, as evidenced by punctate 
staining in confocal microscopy. Interestingly, therefore, although LPS upregulates p62 (Fig. 4b,c), this increased 
expression (2.59 ± 0.94 fold at 18 h, n = 6 independent experiments) is not significantly enhanced by treatment 
of the cells with a variety of inhibitors (E64d plus pepstatin A, NH4Cl or 3-methyladenine [3MA]) that target 
Figure 2. ES-62- and LPS-matured DCs exhibit differential responses in vivo. (a,b) BmDCs were 
cultured ± 2 μ g/ml ES-62 and/or 10 μ g/ml OVA323-339 and then ± LPS (1 μ g/ml) prior to transfer (2.5 × 105) to 
BALB/c mice that had previously received CFSE-labelled KJ1.26+CD4+ T cells (2.5 × 106). Untreated bmDCs 
or those not loaded with OVA peptide provided “None” and “No Ag” controls, respectively. (a) Flow cytometric 
analysis of % of CD4+ KJ1.26+ T cells in the DLN after DC inoculation presented as the mean values ± SEM of 
individual mice pooled from 2 independent experiments where ***p < 0.001 for LPS (n = 5) versus ES-62 + LPS 
(n = 6). Proliferation as indicated by CFSE staining is shown for a representative mouse from each group on  
day 5. (b) In a further independent experiment, the % of DLN CD4+ KJ1.26+ T cells (means ± SEM, n = 3) after 
DC inoculation are shown along with IL-12p40 production by day 3 DLN cells, stimulated ex vivo with medium 
or OVA323–339 for 72 h. Data are mean values ± SEM, n = 3 individual mice, where **p < 0.01 and ***p < 0.001 
for the relevant Medium or OVA-stimulation in the LPS versus ES-62 + LPS groups.
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Figure 3. ES-62 selectively downregulates PKCδ expression in DCs. BmDCs were treated as described in 
Fig. 1 for up to 18 h with ES-62, LPS or incubated in medium alone (N, at 18 h time point) and analysed for 
PKC-α (ai,ii), PKC-ε (bi,ii) or PKC-δ (di,ii) expression by Western blotting and quantitated relative to β-Actin 
and normalised to the 18 h medium control (N) from single experiments. Supporting the reproducibility 
of these findings, data normalised X-fold to the medium control from all the independent 18 h time-point 
Western blotting experiments performed in this study (other data not shown apart from relevant PKC-δ 
samples presented in Figs 4 and 7) are summarised here, expressed as mean values ± SEM where n = number 
of independent experiments, except in the case of PKC-α , where data are from 2 independent experiments 
and expressed as mean values. Thus for PKC-α : ES-62–2.17; LPS–1.28; PKC-ε : ES-62–0.77 ± 0.18, n = 4; 
LPS–1.56 ± 0.16, n = 4; PKC-δ : ES-62–0.56 ± 0.04, n = 12 p < 0.001; LPS–1.05 ± 0.13, n = 10. LPS-mediated 
cytokine release was measured by ELISA from DCs derived from matched WT or PKC-α (aiii, c) and PKC-ε 
(biii, c) mice. The data in aiii and biii are means ± SD, n = 3 from single experiments representative of at least 
3 independent experiments whilst in c, the data are presented as means ± SD, n = 3 from single experiments. 
In diii, WT bmDCs were treated with control or PKC-δ -specific siRNA and then levels of PKC-δ expression 
determined by FACE assay and IL-12p70 or IL-23 measured by ELISA. In an independent experiment, 
treatment of DCs with siPKC-δ also suppressed LPS-stimulated IL-6 production by some 15% relative to the 
levels observed in the sham-treated control cells. Where indicated, *p < 0.05 **p < 0.01 and ***p < 0.001.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:37276 | DOI: 10.1038/srep37276
Figure 4. ES-62 downregulates PKC-δ via autophagolysosomal degradation. (a) Following incubation 
in medium (None) ± LPS or ES-62 for the indicated time DCs were stained for p62 (green; specificity 
demonstrated by p62 epitope blocking peptide [BP]) and cell nuclei (DAPI; Blue). Scale bars are shown in 
red (10 μ m; magnification x63; scan zoom 1; digital zoom 2). (b) DCs pre-treated with autophagolysosomal 
inhibitors E64d plus pepstatin A (EP), 3MA or not (None) were incubated in medium ± ES-62 for 18 h and then 
incubated in medium ± LPS for a further 18 h, annotated as medium alone (N), ES-62 (E), LPS (L) or ES-62+ 
LPS (EL). Alternatively, DCs treated with NH4Cl or not (None) were cultured with these modulators for the 
times (hours) indicated. p62 expression was determined by Western blot analysis. (c) The effect of EP or NH4Cl 
on ES-62- and/or LPS-modulation of p62 expression at 36 h, as determined by Western Blotting relative to the 
appropriate medium control (None/None). Data represent mean values ± SEM, collated from a number of 
independent experiments (n values) where *p < 0.05 for ES-62 relative to the None/None and None/LPS  
(all n = 6) but not None/ES-62+ LPS (n = 4) groups and red **p < 0.05 for ES-62 versus ES-62 + EP (n = 4) and 
ES-62+ NH4Cl (n = 3). All data presented are from at least 3 independent experiments, apart from those in the 
NH4Cl/ES-62 + LPS group, where data are from 2 independent experiments and presented as mean ± range. 
(d) DCs were incubated in medium alone (N; 18 h) or containing ES-62 for 2, 6 or 18 h as indicated in the 
presence and absence of the specified inhibitors and PKC-δ expression determined by Western Blot analysis. 
Quantitative analysis of the effect of 3MA on PKC-δ expression (fold medium control) is shown (d; right hand 
panels). (e) Data for the effects of EP and NH4Cl on ES-62-mediated downregulation of PKC-δ expression at 
18 h, normalised to the relevant medium control (None) are collated from 7 independent experiments for the 
None (no inhibitor) cohorts and from 3 independent experiments for each of the EP and NH4Cl cohorts and 
presented as means ± SEM, where *p < 0.05.
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different aspects of the autophagolysosomal pathway27,28, suggesting a potential block in autophagic flux in LPS 
treated cells.
By contrast, ES-62 induces downregulation of p62 (0.55 ± 0.05 fold at 18 h relative to the None group, n = 6 
independent experiments) to levels that are significantly different to those observed in either control (None) or 
LPS-, but not ES-62 plus LPS-treated cells (Fig. 4b,c), suggesting that exposure to ES-62 can also antagonise the 
LPS-mediated upregulation of p62: however, this modulation is somewhat lost under conditions suppressing 
autophagic flux where, apart from the prevention of ES-62-mediated downregulation of p62, there are no signifi-
cant differences in expression of this transducer amongst the treatment groups (Fig. 4b,c).
Collectively, these data suggest that ES-62, but not LPS, is inducing autophagic flux as evidenced by its apparent 
autophagolysosomal degradation of components of the autophagy machinery, like p62. They also suggest that ES-62 
may exploit this homeostatic mechanism to selectively degrade certain key signalling elements, like PKC-δ 19,20,29  
to subvert classical TLR4 signalling: consistent with this, analysis of the effect of the autophagolysosomal inhibi-
tors on PKC-δ expression reveals that treatment with these prevents the degradation resulting from exposure to 
ES-62 (Fig. 4d,e).
Further support for ES-62, but not LPS, inducing autophagic flux is provided by Western Blot analysis 
(Fig. 5ai,ii) of expression of LC3-I and LC3-II as the ratio of LC3-II/LC3-I expression (Fig. 5aiii) reflects the 
dynamic phosphatidylethanolamine conjugation and autophagy vesicle association of LC3-II generated from 
the cytosolic LC3-I form27. This reveals that whilst LPS can stimulate an increase in LC3-I and to a lesser extent, 
LC3-II expression (relative to β -actin), neither molecule is substantially affected by treatment with either E64d 
plus pepstatin A or NH4Cl. Rather, LPS-stimulation for 36 h appears to result in a decrease in the LC3-II/LC3-I 
ratio relative to that observed in untreated (None) cells (Fig. 5ai: None/None, 1.306, None/LPS, 0.545; Fig. 5aii: 
None/None, 2.027, None/LPS, 0.144, where values shown are the LC3-II/LC3-I ratios). This decrease is main-
tained even in the presence of the autophagolysosomal inhibitors (Fig. 5ai: EP/None, 2.044, EP/LPS, 0.600; 
Fig. 5aii: NH4Cl/None, 1.620, NH4Cl/LPS, 0.102).
By contrast, treatment with ES-62 for 36 h increases the LC3-II/LC3-I ratio in the absence and presence of 
the inhibitors (Fig. 5ai: None/ES-62, 1.614, EP/ES-62, 2.473; Fig. 5aii: None/ES-62, 2.505, NH4Cl/ES-62, 1.795) 
relative to the appropriate control group. Moreover, pretreatment with ES-62 can reduce the LPS block in the 
presence and/or absence of E64d plus pepstatin A or NH4Cl (Fig. 5ai: None/ES-62 + LPS, 0.590, EP/ES-62 + LPS, 
0.977; Fig. 5aii: None/ES-62 + LPS, 1.072, NH4Cl/ES-62 + LPS, 1.102). Analysis of several independent experi-
ments shows that the effects of ES-62 at 18 h do not achieve statistical significance relative to the relevant con-
trol group: nevertheless, the LC3-II/LC3-I ratio levels pertaining in the EP/ES-62 group are significantly higher 
(p < 0.05) than in the None/None cohort (Fig. 5aiii), supporting the proposal that ES-62 induces dynamic auto-
phagic flux27. Moreover, this analysis does confirm the significant suppression of autophagic flux elicited by LPS 
relative to untreated (None) or ES-62-exposed cells at 18 h, even in the presence of the inhibitors of autophagic 
flux.
Furthermore, and consistent with TLR4 signalling inducing a block in autophagic flux in DCs, LPS induces 
a distinct pattern of p62 and LC3 staining in bmDCs (Fig. 5b) and a strong accumulation and disperse staining 
of the lysosomal marker, LAMP-1 (Fig. 5c) that is also distinct from the punctate distribution of p62 in such 
cells (Fig. 5b,d): by contrast, there is evidence of a low level of p62 and LAMP-1 co-localisation in ES-62-treated 
cells (Fig. 5d). Intriguingly, therefore, treatment with the proteasomal inhibitor, lactacystin appears to strongly 
enhance the levels of p62, LC3-I and PKCδ in LPS- but not ES-62-treated cells (Fig. 5e–h), suggesting that under 
steady-state conditions, TLR4 signalling might normally target proteasomal degradation of p62/LC3 to prevent 
autophagy homeostatically limiting (PKCδ -mediated) DC cytokine production, and hence allow initiation of 
pro-inflammatory responses.
Blocking of autophagolysomal degradation does not convert ES-62 to a classical TLR4 ligand 
but inhibition of the proteasome limits LPS responses in DCs. The differential proteasomal and 
autophagolysomal targeting of LPS and ES-62 responses suggested that blocking of their respective degrada-
tion machinery might allow conversion of ES-62-TLR4 signalling to a classical LPS phenotype, or vice versa. 
However, treatment with E64d plus pepstatin A (Fig. 6a–c) or 3MA (Fig. 6d–f) did not result in ES-62 inducing 
LPS-like cytokine production and indeed, these inhibitors generally had little apparent effect on either ES-62 or 
LPS responses, although LPS-stimulated IL-12p70 production was reduced (Fig. 6b,e). By contrast, whilst treat-
ment with lactacystin only marginally modulated ES-62 responses, it inhibited LPS-stimulated IL-6, IL-12p70 
and TNFα production by the DCs (Fig. 6g–i).
Blocking of autophagolysomal degradation differentially modulates ES-62-mediated inhibi-
tion of LPS-stimulated cytokine production in DCs. Although blocking of autophagolysomal degra-
dation did not convert ES-62 to a classical TLR4 ligand, the key role of PKC-δ in IL-12p70 production in DCs25 
confirmed here (Fig. 3d) suggested that treatment with E64d plus pepstatin A might prevent the ES-62-mediated 
inhibition of LPS-induced cytokine production by DCs. This indeed turned out to be the case for IL-6, IL-12p70 
and TNF-α (Fig. 7a–c) but not IL-23 (Fig. 7d) production: however, the lack of effect on IL-23 release was consist-
ent with that observed in the cells treated with the PKC-δ -specific siRNA (Fig. 3diii). Moreover, analysis of PKC-δ 
levels revealed that whilst ES-62 reduced the levels of PKC-δ expression in DCs under conditions of steady-state 
and somewhat, under LPS stimulation, this downregulation was not observed in the presence of the autophago-
lysomal inhibitors (Fig. 7e,f).
Finally, further support for autophagolyosmal-mediated degradation of TLR-associated transducers like 
PKC-δ playing a role in the ES-62-mediated dampening of inflammatory responses was provided by the find-
ing that whilst treatment with siPKC-δ could mimic the effect of ES-62 in inhibiting LPS-stimulated IL-12p70 
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Figure 5. ES-62 stimulates autophagic flux. (ai–iii) DCs were incubated in medium ± ES-62 and/or LPS 
for the indicated time in the presence and absence of EP (i) or NH4Cl (ii) and LC3-I (upper band) and LC3-II 
(lower band) expression determined by Western blot analysis. Via quantitative analysis, the levels of LC3-I and 
LC3-II were normalised to the β -actin loading control and then the ratio of LC3-II/LC3-I (LC3-II/β -actin: 
LC3-I/β -actin) determined and statistical analysis (iii) of the effects of the inhibitors on the responses to ES-62 
or LPS at 18 h undertaken. Data are presented as means ± SEM and were collated from the following number 
(n) of independent experiments: None (no inhibitor) cohorts, n = 6; E64d+ pepstatin A cohorts, n = 3; NH4Cl 
cohorts, n = 4. *p < 0.05 and ***p < 0.001 are for the relevant LPS versus None groups, red */** represent 
comparisons between relevant LPS and ES-62 groups and #p < 0.05 for ES-62-EP versus the None/None group. 
No significant differences were detected amongst the LPS groups. (b–d) Following incubation in medium 
(None) ± LPS or ES-62 for 18 h as indicated, DCs were washed, fixed and permeabilised and stained for: (b) p62 
or LC3 (green) expression (magnification x63, scale bars, 20 μ m); (c) LAMP-1 (red) expression; (d) p62 (green) 
and LAMP-1 (red) expression, with cell nuclei counterstained with DAPI (blue; magnification x63; scale bars, 
10 μ m). Data in (b–d) are from independent experiments, and distinct from the experiment presented in Fig. 4. 
(e) DCs were incubated in medium (N for 18 h) or with LPS in the presence or absence (None) of lactacystin for 
2, 6 or 18 h as indicated and p62 and LC3-I expression determined by Western Blot analysis. Relatively under-
exposed films are shown to allow for visual demonstration of the strong increase in their expression in the 
presence of lactacystin. Quantitative analysis of the effect of lactacystin on the ES-62- and/or LPS-modulation of 
p62 (f), LC3-I (g) and PKC-δ (h) expression at the indicated times relative to the appropriate medium control is 
presented and data are from single experiments.
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and IL-6 production (Fig. 3diii and legend), exposure to siATG7 to block autophagic flux by disrupting the 
PE-conjugation of LC3-I, not only resulted in the enhancement of LPS responses but abrogated their inhibition 
by ES-62 (Fig. 7g).
Discussion
ES-62 is a PC-containing immunomodulatory glycoprotein that exhibits protective effects in models of allergic 
and autoimmune disease9,11 by homeostatically resetting the effector: regulatory B cell balance and consequently 
modulating the IL-23/IL-17/IL-22 inflammatory axis2–6,30, dysregulation of which has been implicated in the 
pathogenesis of chronic inflammatory disorders31. Although the precise cellular networks modulated by the 
worm product appear to differ depending on the inflammatory context, ES-62 likely affords protection by acting 
to subvert TLR signalling via partial downregulation of MyD88 expression in effector cells of both innate and 
adaptive immunity3,4,6,9,17. The effect of targeting this key integrator of inflammatory signalling is exemplified by 
the ability of ES-62 to suppress both the priming and maintenance of pathogenic Th17 and IL-17-producing γ δ T 
cells in CIA by targeting MyD88 in both DCs and Th17 cells4,9. Moreover, this data explains at least in part how, 
despite signalling via TLR4/MyD88, ES-62 does not mimic canonical TLR4 ligands in driving proinflammatory 
responses and indeed can inhibit cellular responses to subsequent TLR-2, -4, -9, but not TLR-3, ligands4,7,8,22,32. 
However, ES-62 is not immunosuppressive per se allowing animals and humans, harbouring PC-containing mol-
ecules like ES-62 in their bloodstream, to mount protective responses against infection whilst dampening those 
resulting from aberrant inflammation (reviewed in refs 9 and 33).
This lack of generalised immunosuppression has presumably arisen over the millennia of host-parasite evo-
lution, generating a “safe” mechanism of immunomodulation tailored to specific aberrant inflammatory con-
texts and suggesting that the partial downregulation of MyD88 selectively targets certain regulatory nodes of the 
TLR4 (and other TLR) signalling cascades amplified in allergy and autoimmunity. In investigating this hypoth-
esis here, we focused on the role of PKC-α , -δ and -ε isoforms not only because of their well-established roles 
in mediating proinflammatory TLR signalling in innate cells19,20,34 but also because these have been reported to 
directly associate with TLR-MyD88-Mal complexes29,35–37. Intriguingly, we have previously found ES-62 to differ-
entially regulate the expression of these PKCs depending on the cell lineage, or even functional phenotype and/
or receptor, targeted1,11,17,22. Given the important roles reported for PKC-α in DCs37 and our findings that ES-62 
downregulates its expression in mast cells and B and T cells1,11,17, we were initially rather surprised that ES-62 
did not exhibit differential effects to LPS on expression of this isoform: however, our analysis of DCs derived 
Figure 6. Autophagolysomal inhibitors do not convert ES-62 to a classical TLR4 ligand. DCs were treated 
with ES-62 or LPS for the indicated times in the absence and presence of E64d + pepstatin A (EP, a–c), 3MA 
(d–f) or lactacystin (Lacta, g–i) and the levels of IL-6 (a,d,g), IL-12p70 (b,e,h) and TNFα (c,f,i) determined. 
Data are derived from single experiments (means ± SD, n = 3), where *p < 0.05, **p < 0.01 and ***p < 0.001.
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from PKC-α -deficient mice showed this isoform to be dispensable for full TLR4 signalling, at least in terms of 
IL-6, TNF-α and IL-12p40 production. Likewise, consistent with reports that it associates with MyD8836 and 
mediates LPS-stimulated IL-12-dependent responses in human monocyte-derived DCs38 we find that PKC-ε is 
upregulated by LPS, but not ES-62. However, this PKC isoform also appears to be non-essential for LPS-induced 
cytokine responses in murine bm-derived DCs, perhaps indicating differential roles in DC subtypes or alterna-
tively, redundancy in PKC isoforms.
By contrast, and in keeping with PKC-δ playing key roles in DC development and motility, IL-12p40/p70 
production, MHC II-Ag presentation and polarisation of Th1 responses23–26, we found ES-62, but not LPS, to 
downregulate expression of PKC-δ , typically to about 50% of the levels found under steady-state conditions. 
The functional relevance of this downregulation was indicated by the siRNA-mediated partial knockdown of 
this isoform also resulting in inhibition of LPS-induced IL-6, IL-12p70, but not IL-23, production. Interestingly, 
therefore, downregulation of PKC-δ has been shown to similarly suppress TLR-mediated cytokine production 
in monocytes by inhibiting NF-κ B activation29,39, perhaps reflecting reports that PKC-δ can phosphorylate Iκ 
B resulting in its subsequent ubiquitination and degradation by the 26S proteasome, thereby allowing nuclear 
translocation of NF-κ B and its binding to κ B elements40,41.
Figure 7. Blockade of autophagic flux prevents ES-62-mediated inhibition of LPS-stimulated IL-6, 
TNFα and IL-12p70 but not IL-23 production by DCs. DCs were incubated in medium (None) ± ES-62 
for 18 h and then with medium ± LPS for a further 18 h in the presence and absence of E64d plus pepstatin A 
(EP) and the levels of IL-6 (a), IL-12p70 (b), TNFα (c), and IL-23 (d) released, shown. Data in (a) are from 
a single experiment (means ± SD, n = 3) whereas in b-d, data are the means ± SEM of means collated from 
three independent experiments, where *p < 0.05, **p < 0.01 and ***p < 0.001 relative to the LPS group and 
#p < 0.05 and ##p < 0.01 relative to the LPS-EP group. DCs were incubated in medium ± ES-62 for 18 h and 
then medium ± LPS for a further 18 h in the presence and absence of EP and PKC-δ expression determined 
by Western Blot analysis (e) with quantitation of PKC-δ expression in this experiment relative to None/None 
control shown on the figure. Analysis was of data collated from 5 independent experiments for the None (no 
inhibitor) cohorts and 3 independent experiments for the EP cohorts (f) with data presented as means ± SEM 
where **p < 0.01 for ES-62 versus None and red*p < 0.05 for ES-62 versus LPS. In g, WT bmDCs were treated 
with control or ATG7-specific siRNA and then cultured in medium ± ES-62 prior to stimulation with LPS as 
indicated and then the levels of IL-6 measured by ELISA. Data are presented as means ± SD, n = 3 from a single 
experiment where **p < 0.01 is relative to the LPS-Sham, red***p < 0.001 relative to ES-62+ LPS-Sham and, 
#p < 0.05 relative LPS-sham.
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Interestingly, given that we have found MyD88 expression in DCs to be homeostatically regulated by ES-62 
in an autophagolysosomal manner, as indicated by the blockade of its downregulation by the inhibitors, E64d 
plus pepstatin A9, we show that the selective degradation of PKC-δ by ES-62 is associated with low level, dynamic 
autophagic flux resulting in its autophagolysomal degradation. This is indicated by immunofluorescence analysis 
of p62 and LAMP-1 trafficking and Western blot-detected increases in p62, LC3-II/I ratio and PKCδ expression 
in response to ES-62 in the presence of a variety of inhibitors of autophagic flux27,42. By contrast, although LPS 
induces upregulation and redistribution of p62 and LC3, these are not further increased by autophagolysosomal 
inhibitors and consistent with this, LPS does not direct p62 and LC3 or LAMP-1 co-localisation: collectively, these 
effects of LPS are more consistent with blockage of autophagic flux27,42,43. Indeed, LPS-mediated upregulation of 
p62 and LC3 elements appears to be greatly enhanced by the proteasome inhibitor, lactacystin suggesting that 
this TLR4 ligand also acts to sequester p62 and LC3 from the autophagy machinery, data perhaps in keeping with 
proposals that although TLR-signalling promotes autophagy to effect microbial elimination, induction of auto-
phagic flux may be a key player in the complex homeostatic regulatory networks acting to limit inflammation18.
By inducing low-level autophagic flux, ES-62 may be harnessing this homeostatic network to dynamically 
prevent hyperinflammatory responses, a proposal supported by the finding that treatment with E64d plus pep-
statin A prevents the ES-62-mediated downregulation of IL-6, TNFα and IL-12p70. That this is harnessing of 
a homeostatic mechanism to limit inflammation is perhaps further supported by our findings that use of the 
autophagolysosomal inhibitors does not convert ES-62 into a conventional TLR4 ligand. By contrast, and reflect-
ing independent studies in macrophages44, proteasomal blockade appears to delay and diminish LPS-stimulated 
cytokine production, perhaps by permitting some autophagic flux due to the resulting increased levels of p62. 
Nevertheless, the strong LPS-induced cytosolic p62 signalling observed is reminiscent of that reported in kerat-
inocytes45 where although TLR-signalling promotes p62-dependent autophagy to negatively regulate inflamma-
tion, p62, in keeping with its ability to activate NF-κ B in autophagy-defective tumour cells46,47, also promotes 
NF-κ B activation and consequent inflammatory responses.
Intriguingly, given the ability of LPS, but not ES-62, to upregulate PKC-ε , p62 has been proposed to act as 
an atypical PKC scaffold to generate a PKC-ε /p62/Traf6 complex that is critical for the activation of NF-κ B in 
response to IL-1, TNFα and RANKL48,49 leading to the suggestion that upregulation of cytosolic p62 may, by 
promoting NF-κ B activation, prime TLR-driven inflammatory responses45. Thus, given our preliminary data 
that ES-62 also downregulates Traf6 (Eason, Harnett & Harnett, unpublished), the lack of strong cytosolic p62 
signalling induced by this non-canonical TLR4 ligand may go some way to explaining why blockage of autophagic 
flux does not convert ES-62 to a classical TLR4 ligand. Indeed, treatment with lactacystin appears to be able to 
prevent the early (< 6 h) ES-62-mediated downregulation of p62, suggesting that ES-62 can target both the NF-κ B 
(via the proteasome) and the autophagy-promoting capabilities of p62. This capacity to potentially induce both 
proteasomal and autophagolysosomal degradation of p62 is reminiscent of the ability of ES-62 to exploit both 
proteolytic compartments to downregulate PKCα in mucosal-like bm-derived and peritoneal-derived mast cells 
but not connective tissue mast cells (autophagoloysomal only)17. Collectively, therefore our data suggest that by 
inducing autophagolysomal and proteasomal degradation of key signalling elements, ES-62 can homeostatically 
rebalance aberrant DC-primed Th1 and Th17 responses.
In conclusion, millenia of host-pathogen co-evolution has generated immunomodulators, like ES-62, that 
act to dampen down host inflammation and limit tissue pathology11,50 thereby promoting both parasitic worm 
and host survival. This, in conjunction with the clear inverse relationship between the incidence of parasitic 
helminths and the prevalence of chronic allergic and autoimmune inflammatory disorders globally, has, via the 
Hygiene Hypothesis, generated increasing interest in exploiting such parasites and/or their immunomodulators 
as novel and theoretically safer therapies in chronic human inflammatory diseases11,51–53. Thus, discovering how 
immunomodulators like ES-62 exploit homeostatic regulatory mechanisms, not only informs our fundamental 
understanding of inflammation and its resolution, but can also identify potential novel and safer nodes of inter-
vention in chronic inflammatory disease. Importantly, as ES-62 harnesses autophagic flux to selectively degrade 
TLR signalling elements, transducers that may differ, depending on cell type and/or TLR ligand, this provides the 
potential to homeostatically normalise inflammatory responses irrespective of their phenotype.
Materials and Methods
Animals and ES-62. All animals were maintained under standard ad libitum conditions at the Universities 
of Glasgow and Strathclyde SPF Biological Services Facilities and all experimental procedures were approved by, 
and performed in accordance with, the Animal Welfare and Ethical Review Body at the University of Glasgow, the 
Ethical Review Board of the University of Strathclyde and UK Home Office Regulations and Licenses PPL 60/3046, 
60/2795 and 60/4300. Male, 6–8 week old, wild type BALB/c and C57BL/6 mice purchased from Harlan Olac 
(Bicester, U.K.) were used to generate bone marrow (bm)-derived dendritic cells (DCs) and DO.11.10.BALB/c 
mice and OT-II.C57BL/6 mice (both bred in-house) were used as sources of ovalbumin (OVA323–339)-specific 
transgenic (tg) TCR CD4+ T cells4,21,54,55. Bm-DCs derived from BALB/c mice and OVA323–339-specific tg TCR 
CD4+ T cells from DO.11.10.BALB/c mice were used as donor cells for adoptive transfer to recipient BALB/c mice. 
For PKC isoform−/− studies, PKC-α (C57BL/6-Sv129 background) and –ε (C57BL/6Jax background) deficient 
mice in conjunction with their age and sex matched wild-type controls were used to derive bmDCs. PKC-α −/− 
and PKC-ε −/− mice were generated as previously described22. Bones from each set of PKC-isoform-deficient mice 
and their relevant wild-type genetic background controls were shipped to the University of Strathclyde from the 
donor laboratory group’s animal unit. Endotoxin-free ES-62 was prepared and purified from culture medium 
following maintenance of adult Acanthocheilonema viteae as described previously56.
Analysis of DC function. DCs were derived from femur bone marrow cells from either BALB/c or C57BL/6 
mice by culture in complete RPMI 1640 medium (contains 2 mM glutamine, 50 units/ml penicillin, 50 μ g/ml 
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streptomycin, 50 μ M 2-mercaptoethanol [all Life Technologies, Renfrew UK] and 10% fetal calf serum [Lonza, 
Nottingham UK]), supplemented with 10 ng/ml recombinant murine GM-CSF (Peprotech, London UK), at 37 °C 
in 5% CO2. On day 6, immature bmDCs (65–85% CD11c+) were harvested by gentle scraping and these bmDCs 
were further purified (≥ 95%) by positive selection using CD11c-MACS microbead separation (Miltenyi Biotec, 
Woking, UK) according to the manufacturer’s instructions. CD11c+ DCs (2 × 106 cells) were then incubated in 
medium ± ES-62 (2 μ g/ml) and/or lipopolysaccharide (LPS; 1 μ g/ml) (Salmonella minnesota or, where indicated, 
Escherichia coli, strain 055:B5 [Sigma, Poole UK]) prior to detection of cytokine release by ELISA and/or cell 
signalling events by Western Blotting7,8,17,22,57,58.
For bmDC-T cell co-cultures, DCs were incubated in medium ± ES-62 and/or LPS, prior to pulsing with 
OVA323–339 peptide (0–300 nM) before incubation with naive OVA-specific CD4+CD62L+ T cells from DO.11.10.
BALB/c or OT-II.C57BL/6 mice, isolated using Miltenyi magnetic bead technology4,21,54,55,58. In some experi-
ments, the transgenic (tg) TCR T cells, detected using the clonotypic monoclonal Ab KJ1.26, were labelled 
with 5, 6-Carboxy-Succinimidyl-Fluorescein-Ester (CFSE; 5 μ M) and assessed for cell phenotype and prolif-
eration by flow cytometry as previously described, using a Becton Dickinson FACSCalibarTM flow cytometer 
(BD Biosciences, Oxford UK) and analysed using Flowjo software (Tree Star Inc, OR, USA, version 8.8.6)4,5,21,54.
Where indicated, to block autophagic flux28, DCs were treated with a combination of E-64d plus pepstatin A 
(both 10 μ g/ml; Enzo Life Sciences, Exeter UK) to raise the pH of lytic granules and inhibit lysosomal proteases, 
respectively, NH4Cl to neutralise lysosomal pH (50 μ M) or 3MA (2 mM) to inhibit the Class III PtdIns-3-K sig-
nalling essential for the early stages of autophagy28. Alternatively, the proteasomal degradation inhibitor lacta-
cystin (10 μ M; Enzo Life Sciences, Exeter UK), which inhibits the ATP independent activities of the proteosome, 
was also utilised in these studies as we described previously17. For the siRNA studies, Qiagen PKC-δ and Allstar-3 
control siRNA were used at a final concentration of 1 nM according to Qiagen and PolyPlus manufacturers’ proto-
cols (Qiagen, Manchester UK). Briefly, DCs were plated at 104 cells/well and allowed to rest before being exposed 
to two treatments with siRNA in INTERFERin siRNA transfection reagent (PolyPLus) at 24 and 48 h and then 
after a further 2 h, cells were treated with LPS and 18 h later cell supernatants harvested for analysis of cytokine 
release by ELISA. Cells were also analysed by FACE assays as we described previously8 using a rabbit anti-PKCδ 
(clone 2058; Cell Signalling, Leiden, Netherlands) and a HRP-conjugated anti-rabbit IgG polyclonal antibody 
(Cell Signalling, Leiden, Netherlands).
For the adoptive transfer studies, bmDCs were prepared as described above and harvested on day 6. Cells 
(2 × 106/well) were then cultured in 6 well plates in the presence or absence of 2 μ g/ml ES-62 and 10 μ g/ml (5 μ M) 
OVA323–339 peptide. Where indicated, after 24 h, the DCs were further stimulated with 1 μ g/ml E. coli 055:B5 LPS 
for 24 h. On day 8, non-irradiated, age matched, male BALB/c recipient mice that had been adoptively transferred 
with 2.5 × 106 KJ1.26+CD4+ DO.11.10 T cells i.v.21,54 one day earlier were then injected s.c. in the left hind footpad 
with 2.5 × 105 bmDCs.
ELISA. IL-6, TNF-α (both eBioscience, Hatfield UK), IL-12p40, IL-12p70, IL-22, IL-23 (all R&D, Abingdon 
UK) and IL-17A (Biolegend, London UK) cytokine ELISA analysis was performed according to the manufactur-
er’s instructions.
Western Blotting. Western Blot analysis was carried out as described previously8,17,22,58. Briefly, bmDC 
(2 × 106 cells/treatment) reactions were terminated by washing with ice cold PBS before lysing and solubilising 
cells in 50 μ l modified RIPA buffer (50 mM Tris buffer, pH 7.4 containing 150 mM sodium chloride, 2% (v/v) 
NP-40, 0.25% (w/v) sodium deoxycholate, 1 mM EGTA, 0.5 mM phenylmethylsulfonylfluoride [PMSF], 1 in 100 
dilutions of HaltTM Protease and Phosphatase Inhibitor Cocktails [Thermo Scientific, Renfrew, UK]). Protein con-
centrations were assessed by the BCA protein assay (Pierce [Thermo Fisher] Renfrew, UK) and equal amounts of 
samples were resolved and proteins transferred to nitrocellulose membranes using the XCell SureLock Mini-cell 
kit with NuPAGE Novex “high performance” pre-cast Bis-Tris gels and NuPAGE buffers and reagents (all sup-
plied by Invitrogen, Renfrew, UK). Nitrocellulose membranes were blocked in TBS/Tween 20 containing 5% 
non-fat milk protein and all antibodies were diluted in TBS/Tween 20 with 5% BSA. Protein bands were visualised 
using the NOVEX® ECL HRP Chemiluminescent detection system (Invitrogen, Renfrew UK) and autoradi-
ography film, with densitometry performed using Image J software. Antibodies with the following specificities 
were used: p62 (SQSTM1): #NPB1-42821 (Novus Biologicals, Abingdon UK); PKCα : #610107, (BD Bioscience, 
Oxford UK); PKCδ : #2058; PKCε : #2683; LC3A/B #4018 and HRP-conjugated anti- mouse or anti-rabbit IgG 
polyclonal antibodies (all Cell Signalling Technologies, Leiden Netherlands). The data presented in the main text 
figures are cropped blots but representative full-length images of the relevant antibody specificities are shown and 
cross-referenced in Supplementary Figure 1.
RT-PCR. Preparation of RNA and consequent RT-PCR analysis was performed as described previously4,32. 
Briefly, RNA was extracted using the RNeasy micro kit (Qiaqen, Manchester UK) prior to DNase (Invitrogen, 
Renfrew UK) digestion and cDNA preparation using the “High Capacity cDNA Reverse Transcription 
Kit” (Applied Biosystems, ThermoFisher, Renfrew, UK) as per the manufacturer’s instructions. TaqMan 
RT-PCR was performed in a 7900 HT Sequence Detector (Applied Biosystems, ThermoFisher, Renfrew, UK) 
using pre-designed Applied Biosystems primer/probe kits (GAPDH, #-4352339E; HPRT, #-4331182; IL-17 
Mm00439618_m1 and IL-22 Mm00444241_m1) with thermal cycler conditions as follows: 20 seconds at 95 °C, 
followed by 45 two-temperature cycles (3 seconds at 95 °C and 30 seconds at 60 °C) with a final step of 60 °C 
for 30 seconds. Data analysis was completed using RQ Manager Software (Applied Biosystems, ThermoFisher, 
Renfrew, UK) and expressed as Rq values where the 2^−Δ Δ Ct values have been determined relative to the 
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house-keeping reference gene (GAPDH) and experimental control samples, namely the medium-only DCs 
(None; 0 nM OVA peptide).
Immunofluorescence. Immunofluorescence was performed as described previously4,5,32. Briefly, cells were 
fixed with 4% paraformaldehyde (PFA), permeabilised with 0.1% (v/v)Triton-x in PBS and incubated with 0.3 M 
glycine in PBS to reduce cellular autofluorescence. Blocking of non-specific binding was performed with 1% BSA 
and 10% normal goat serum (Invitrogen, Renfrew UK), or the appropriate species for the secondary antibody, 
for 30 min and specificity of reactivity validated by the relevant epitope blocking peptide. Cells were counter-
stained with 4′ ,6- DAPI and mounted in Pro-long Gold anti-fade mounting medium (Invitrogen, ThermoFisher, 
Renfrew, UK). Images were acquired and analysed on a Zeiss LSM510 confocal microscope using LSM Image 
Browser software.
Statistical Analysis. Parametric data were analyzed by Student’s unpaired t-test or by one-way ANOVA 
followed by the Bonferroni’s post-test. Normalized data were analyzed by Kruskal-Wallis test.
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